Galderma announces progress with RelabotulinumtoxinA regulatory submissions

2023年10月07日 23:06:18 来自: (0)参与

Galderma receives FDA Complete Response Letter with comments isolated to Chemistry, Manufacturing, and Controls items

International Chamber of Commerce (ICC) arbitration is complete and the regulatory applications are under review

Regulatory filings in other territories are ongoing and remain on track

ZUG, Switzerland--(BUSINESS WIRE)--Galderma, the emerging pure-play dermatology category leader, announced today updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA (QM-1114) to the U.S. Food and Drug Administration (“FDA”).

The FDA has issued a Complete Response Letter (“CRL”) to Galderma related to its BLA for RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines (frown lines) associated with corrugator and/or procerus muscle activity in adult patients as well as moderate-to-severe lateral canthal lines (crow’s feet) associated with orbicularis oculi muscle activity in adult patients.

The CRL points out certain deficiencies isolated to items related to Chemistry, Manufacturing, and Controls (“CMC”) processes. All other aspects of the BLA, including safety and efficacy related parts, did not solicit deficiencies to be addressed. Galderma has already identified changes to the manufacturing process to address feedback. It will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant issues.

Further update on the regulatory filing strategy of RelabotulinumtoxinA and broader neuromodulator R&D partnership

On September 28, 2023, the International Chamber of Commerce (ICC) issued its award on the arbitration commenced by Galderma in 2021 regarding the regulatory filing strategy for RelabotulinumtoxinA, and as a result, the arbitration is complete. While the award is confidential, the result is that the applications submitted for regulatory review are proceeding according to the initial strategy and Galderma and Ipsen await further feedback from regulators.

Galderma remains responsible for development, regulatory filing and strategy, manufacturing, and commercialization. Interactions with regulatory authorities remain the responsibility of Galderma. Regulatory approval submissions and issued certificates will ultimately be in the name of Ipsen.

The ICC award has no impact on the ongoing European decentralized procedure for the filing of RelabotulinumtoxinA nor on the commercialization of Galderma’s neuromodulator portfolio. Regulatory submissions in other territories are ongoing and remain on track.

Furthermore, in a press release dated July 27, 2023, Ipsen made statements about the purported termination of the Galderma-Ipsen Research and Development (R&D) partnership. Galderma contests those statements and remains committed to resolution with Ipsen.

Galderma remains committed to bringing scientific innovation to its healthcare professionals, consumers and patients globally by expanding its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market.

About Galderma

Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. Galderma’s portfolio of flagship brands includes Restylane®, Dysport®, Azzalure®, Alluzience® and Sculptra® in Injectable Aesthetics; Soolantra®, Epiduo®, Differin®, Aklief®, Epsolay®, Twyneo®, Oracea®, Metvix®, Benzac® and Loceryl® in Therapeutic Dermatology; and Cetaphil® and Alastin Skincare® in Dermatological Skincare. For more information: www.galderma.com.

相关新闻
网易网友:我也有过期待
评论:信就是信,不信就是不信,你丫的还微信。

其它网友:念旧-  Tender
评论:笑容是馈赠别人的见面礼,眼泪是洗涤自我的沐浴露。

淘宝网友:半日情obsessIOn
评论:学习伤我千千遍,我待学习如初恋。

猫扑网友:遗忘。Forgotten.
评论:暧昧的本质是激情,而爱情的本质是平淡。

凤凰网友:﹎拿命再愛√
评论:向上爬时,对遇到的人好点,因为掉下来时,你还会遇到他们。

本网网友:挂念 - hcs/u3
评论:儿子要穷养,长大了才知道奋斗;女儿要富教,长大了才不会被诱惑。

百度网友:Alexandr 嫁衣°
评论:过着八戒的生活,却想要悟空的身材。

天猫网友:情是无所不为
评论:职场三定律;:要么忍!要么狠!要么滚!

搜狐网友:旧情歌-TRISTE
评论:如果我死了,唯一放不下的就是我的QQ。

天涯网友:流受ranmuy/
评论:成熟的人不问过去,聪明的人不问现在,豁达的人不问将来。

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin